Cargando…

First‐line steroid treatment for spontaneous intracranial hypotension

BACKGROUND: Spontaneous intracranial hypotension (SIH) is a syndrome characterized by low cerebrospinal fluid (CSF) pressure and postural headaches, and affects 1 per 20,000 individuals every year. CASE REPORT: We report an otherwise healthy 38‐year‐old man admitted to the hospital with orthostatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tonello, Simone, Grossi, Ugo, Trincia, Elena, Zanus, Giacomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Headache
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303736/ https://www.ncbi.nlm.nih.gov/pubmed/35141990 http://dx.doi.org/10.1111/ene.15195

Ejemplares similares

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

Update on Idiopathic Intracranial Hypertension Management
por: Souza, Marcio Nattan Portes, et al.
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

Headache due to Bilateral Subacute Subdural Hematomas following Intracranial Hypotension Caused by Cervical Disc Herniation
por: Steenstraten, Iris, et al.
Publicado: (2021)

Spontaneous intracranial hypotension: two steroid-responsive cases
por: Russo, Camilla, et al.
Publicado: (2018)

Pediatric Intracranial Hypertension
por: Sivaswamy, Lalitha
Publicado: (2016)

Intracranial Hypertension in Children without Papilledema
por: Chelse, Ana B., et al.
Publicado: (2015)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Headaches and obesity
por: Fortini, Ida, et al.
Publicado: (2022)

Vestibular migraine
por: Silva, Viviane Passarelli Ramin, et al.
Publicado: (2022)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Behavioural intervention in medication overuse headache: A concealed double‐blind randomized controlled trial
por: Pijpers, Judith A., et al.
Publicado: (2022)

Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010)

Cold extremities in migraine: a marker for vascular dysfunction in women
por: Linstra, K. M., et al.
Publicado: (2020)

Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature
por: Fernández‐de‐las‐Peñas, César, et al.
Publicado: (2021)

Chronic migraine: Genetics or environment?
por: Chalmer, Mona Ameri, et al.
Publicado: (2021)

Multinational descriptive analysis of the real‐world burden of headache using the Migraine Buddy application
por: Goadsby, Peter J., et al.
Publicado: (2021)

Functional connectivity changes in complex migraine aura: beyond the visual network
por: Silvestro, Marcello, et al.
Publicado: (2021)

Successful steroid treatment of coma induced by severe spontaneous intracranial hypotension
por: Goto, Shunsaku, et al.
Publicado: (2016)

Acute Treatment Regimens for Migraine in the ED
por: Millichap, J. Gordon
Publicado: (2015)

Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study
por: Grosberg, Brian, et al.
Publicado: (2021)

Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials
por: Hindiyeh, Nada A., et al.
Publicado: (2019)

Spontaneous intracranial hypotension: case report
por: Merlo, P., et al.
Publicado: (2005)

Spontaneous intracranial hypotension with pituitary adenoma
por: Firat, A. K., et al.
Publicado: (2006)

Spontaneous intracranial hypotension with pituitary adenoma
por: Firat, Ahemt K., et al.
Publicado: (2007)

Spontaneous intracranial hypotension with pituitary adenoma
por: Firat, Ahmet K., et al.
Publicado: (2008)

Reversible Syringomyelia in Spontaneous Intracranial Hypotension
por: Oh, Seung Taek, et al.
Publicado: (2023)

Diagnosis and treatment evaluation in patients with spontaneous intracranial hypotension
por: Mehta, Dwij, et al.
Publicado: (2023)

www.cefalea.it: the first five years
por: Rossi, P., et al.
Publicado: (2005)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 infection altered the factors associated with headache: evidence from a multicenter community-based case–control study
por: Ali, Mohammad
Publicado: (2022)

Section editor note
por: Zanchin, Giorgio
Publicado: (2006)

Neurophysiological approach to central pain modulation in primary headaches
por: Rossi, P., et al.
Publicado: (2005)

Habituation of single CO(2) laser–evoked responses during interictal phase of migraine
por: de Tommaso, M., et al.
Publicado: (2005)

Medication–overuse headache: pathophysiological insights
por: Calabresi, P., et al.
Publicado: (2005)

When cluster headache was called histaminic cephalalgia (Horton’s headache)
por: Fanciullacci, M.
Publicado: (2006)

Review of Prevention for Pediatric and Adolescent Migraine
por: Qubty, William, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fa2287s2944cepu81ajbeif9s9